Oxymetholone hepatotoxicity: 17-alpha-alkylation and liver load
Oxymetholone is one of the most potent oral anabolic steroids and also one of the most hepatically demanding. The root of its liver toxicity lies in a single chemical feature shared across oral steroids: 17-alpha-alkylation. This editorial overview explains the chemistry, the documented risks, and why the liver pays the price.
What oxymetholone is
Oxymetholone is a synthetic anabolic-androgenic steroid taken by mouth, derived from dihydrotestosterone. It is a potent agent that was developed in the 1960s and has legitimate medical uses, principally in the treatment of certain anaemias, including those due to bone-marrow failure, where it can stimulate red-blood-cell production. It has also been studied in wasting conditions.
In the UK, oxymetholone is a prescription-only and controlled substance. Its medical use is confined to specific, supervised situations where its benefits are judged to outweigh its considerable risks. It is not a routine treatment, precisely because of the hepatic and other hazards discussed here.
Among oral steroids, oxymetholone has a reputation for both strong effects and significant toxicity. That toxicity is not incidental; it is closely tied to the chemical modification that makes the drug orally active in the first place, which is the subject of this article.
The focus here is on the mechanism of liver toxicity, not on how the drug is used. Understanding why 17-alkylated steroids strain the liver is useful for anyone seeking to interpret the warnings that accompany this entire class of medicines.
The chemistry of 17-alpha-alkylation
To work when swallowed, a steroid must survive the liver's first-pass metabolism — the intensive processing that occurs when blood from the gut passes through the liver before reaching the rest of the body. Plain testosterone is almost entirely inactivated at this stage. Attaching an alkyl group (a methyl group in oxymetholone) at the 17-alpha position blocks the enzymes that would normally inactivate the molecule.
This 17-alpha-alkylation is the shared feature of oral anabolic steroids, including oxymetholone, oxandrolone, stanozolol and methandrostenolone. It is what makes them orally active. But the same resistance to normal metabolism that lets the drug survive also forces the liver to handle a molecule it cannot easily clear, and this is the origin of the class's hepatotoxicity.
In short, the feature that is a benefit — oral activity — is inseparable from the feature that is a hazard — resistance to clearance and consequent liver burden. This trade-off defines the oral steroid class, and oxymetholone sits at the more toxic end of it.
It is worth emphasising that injectable steroids, which are not 17-alkylated, generally do not carry the same degree of direct liver toxicity. The hepatic concern is largely specific to the orally active alkylated compounds, which is why their labels and the literature single out the liver.
How the liver is harmed
The liver damage from 17-alkylated steroids takes several forms. The most common is a rise in liver enzymes, reflecting irritation or injury to liver cells. More specifically, these steroids can impair the flow of bile — a condition called cholestasis — leading to jaundice (yellowing of skin and eyes) and itching. This cholestatic pattern is a recognised signature of the class.
A rarer but more serious problem is peliosis hepatis, in which blood-filled cystic spaces form within the liver. These can, uncommonly, rupture and cause internal bleeding. Long-term use has also been associated with the development of liver tumours, both benign (hepatic adenomas) and, rarely, malignant. These severe outcomes are documented in the medical literature on anabolic steroids.
The degree of harm is dose- and duration-dependent: higher exposure and longer use raise the risk. Individual susceptibility also varies, so liver injury can occur unpredictably. The combination of a potent agent like oxymetholone with prolonged use represents the higher end of hepatic risk within the class.
These effects are not merely theoretical warnings copied from a datasheet. They are the reason oxymetholone's medical use requires regular liver monitoring and why its risk-benefit balance is reserved for serious conditions where alternatives are limited.
Documented hepatic risks
The table summarises the recognised liver-related risks associated with 17-alkylated oral steroids such as oxymetholone, drawn from clinical and toxicological literature. The point is not to alarm but to be honest about a well-characterised hazard.
| Hepatic effect | Nature | Relative frequency |
|---|---|---|
| Raised liver enzymes | Hepatocyte irritation/injury | Common with use |
| Cholestasis / jaundice | Impaired bile flow | Recognised, dose-related |
| Peliosis hepatis | Blood-filled hepatic cysts | Rare but serious |
| Hepatic adenoma | Benign liver tumour | Rare, with prolonged use |
| Hepatocellular carcinoma | Malignant tumour | Very rare, reported |
Beyond the liver, oxymetholone shares the broader anabolic-steroid risk profile: suppression of the body's own testosterone, adverse effects on cholesterol (notably lowering protective HDL), fluid retention, and — in women — virilising effects. The hepatic concern is the most distinctive feature of the oral route, but it is not the only risk.
It is also relevant that oxymetholone, despite deriving from dihydrotestosterone, is associated with oestrogenic-type side effects such as fluid retention and, in some, gynaecomastia, through mechanisms not fully explained by simple aromatisation. This complicates the picture and underlines that the drug is not straightforwardly "mild" in any respect.
The cumulative message from the literature is consistent: oral 17-alkylated steroids, and oxymetholone prominently among them, carry a real and well-documented burden of liver toxicity that rises with dose and duration.
Warning signs and monitoring
Because liver injury can develop during use of 17-alkylated steroids, monitoring is central to any medical use. Liver blood tests are checked before and periodically during treatment, so that rising enzymes or signs of cholestasis can be caught early and the drug stopped or reviewed. This monitoring is not optional in the clinical setting.
The warning signs of liver trouble are important to recognise. Yellowing of the skin or eyes, dark urine, pale stools, persistent itching, right-sided upper abdominal pain, nausea and unusual fatigue all warrant prompt medical attention. These are general signals of liver stress and should never be ignored.
- Jaundice (yellow skin or eyes) — seek urgent assessment.
- Dark urine / pale stools — signs of impaired bile flow.
- Right upper abdominal pain — possible hepatic involvement.
- Unexplained fatigue or nausea — warrants blood tests.
Avoiding additional liver insults matters too. Alcohol and other hepatotoxic substances compound the strain, and combining them with an alkylated oral steroid increases risk. Anyone using such a drug, medically or otherwise, reduces danger by minimising other liver stressors.
Ultimately the only way to eliminate the hepatic risk of an oral alkylated steroid is not to take one. Where a genuine medical need exists, the decision, dosing and monitoring belong with a specialist who can weigh the serious risks against the specific benefit in that patient.
Conclusions of the editorial team
Oxymetholone's liver toxicity is not a quirk but a direct consequence of the 17-alpha-alkylation that makes it orally active. The chemistry that lets the drug survive the liver also forces the liver to handle a molecule it cannot easily clear, producing raised enzymes, cholestasis and, rarely, serious outcomes such as peliosis hepatis and liver tumours.
The risks are dose- and duration-dependent and well documented, which is why medical use is reserved for serious conditions and accompanied by regular monitoring. The warning signs of liver injury deserve to be widely known, because early recognition matters.
Our related material on the metabolism of oral steroids, on reading a liver function test, and on the broader cardiovascular and hormonal risks of anabolic steroids develops these points further.
References
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Anabolic steroids. Bethesda: NIDDK; 2020.
- Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver. 1992;12(2):73–79.
- Electronic Medicines Compendium. Oxymetholone: prescribing information. Datapharm; 2021.
- Niedfeldt MW. Anabolic steroid effect on the liver. Curr Sports Med Rep. 2018;17(3):97–102.
